Forbion is proud to serve as a Regional Host of Grand Rounds: Europe, taking place 23–25 September in Amsterdam, alongside BioGeneration Ventures (BGV).
Geert-Jan Mulder, MD, Managing Partner, will moderate the session “The Expanding Reach of Estrogen: Decoding Its Role Across Women’s and Systemic Diseases” on 25 September from 10:00–10:45 AM. He will be joined by Karen Chan, Ph.D., Senior Director at Lilly Gateway Labs, Eli Lilly, and Diana Torgersen, D.Phil., Managing Director at Torgersen Advisory.
Vanessa Carle, PhD, Principal, will moderate the Horizon Session “Rewriting Vascular Biology: Integrating Immune, Thrombotic, Genetic, and Metabolic Levers for New CV Therapeutics” on 25 September from 11:15 AM–12:00 PM. The session will explore how advances across vascular biology are opening new avenues for the development of cardiovascular therapeutics.
She will be joined by leading experts from NewAmsterdam Pharma, Regeneron Genetics Center, Leiden University Medical Center, and KU Leuven to discuss emerging science and its potential to translate into new therapeutic approaches for cardiovascular disease.
The meeting brings together venture investors, biopharma leaders, academic innovators, and biotech founders to address the translational challenges that stand between breakthrough science and patient impact. Through scientific presentations and candid discussions, the programme explores the opportunities and barriers shaping the next generation of therapeutics.
Grand Rounds: Europe provides a unique forum for connecting innovators, investors, and industry leaders, fostering the collaborations needed to accelerate the translation of scientific discoveries into new medicines.
Learn more about the program, presenting companies, sponsors, and speakers by downloading the conference brochure here.